Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02460822 · ClinicalTrials.gov registry record · NA

Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management

A NA study, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
16
Enrollment target

NCT02460822: Completed NA study, sponsored by University of Michigan.

NCT02460822 is a NA study that has completed, run by University of Michigan. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02460822, a NA study, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target

Study Summary

This research project addresses critical gaps in cancer symptom management through the creation of a mobile chemotherapy symptom management application. This application will assess for the presence and severity of common chemotherapy side-effects and provide personally tailored symptom-related video and narratives to enhance self-management of cancer and treatment-related symptoms. This study will examine patient acceptance and use of this mHealth application (called MyChemoCare) in a prospective trial of cancer patients (n=60) who are receiving chemotherapy for colorectal cancer at the University of Michigan Comprehensive Cancer Center.

Primary Outcome

Patient retention is defined as the number of patients who completed the 8-week study through the final evaluation. Engagement with the MyChemoCare application was measured as number of patients who checked in at least once per week of the study.

Interventions

  • DEVICE MyChemoCare iPad application

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2014-10
Est. Completion 2015-11
Phase NA
University of Michigan

1,327 total trials

What the finished NCT02460822 record still lists

NCT02460822 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which MyChemoCare iPad application is the first listed.

NCT02460822 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02460822 about?

NCT02460822 is a clinical study titled "Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management". This research project addresses critical gaps in cancer symptom management through the creation of a mobile chemotherapy symptom management application. This application will assess for the presence and severity of common chemotherapy side-effects and provide personally tailored symptom-related vide...

What is the current status of trial NCT02460822?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2014-10. Estimated completion is 2015-11.

What interventions are being tested in trial NCT02460822?

The interventions under investigation include: MyChemoCare iPad application (DEVICE).

Who is sponsoring clinical trial NCT02460822?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02460822's enrollment target sits among peer trials

16 1871st of 2000 higher than 120 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02460822, the US trial registry maintained by the National Library of Medicine. NCT02460822 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.